Bank Of America Corp Gritstone Bio, Inc. Transaction History

Bank Of America Corp

$1.12 Trillion
Q2 2024

A detailed history of Bank Of America Corp transactions in Gritstone Bio, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 85,007 shares of GRTS stock, worth $1,700. This represents 0.0% of its overall portfolio holdings.

Number of Shares

85,007

Previous 85,339 0.39%

Holding current value

$1,700

Previous $219,000 76.26%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.62 - $2.35 $205 - $780	-332 Reduced 0.39%	85,007 $52,000
Q1 2024 May 15, 2024	SELL	$1.96 - $2.9 $200,294 - $296,353	-102,191 Reduced 54.49%	85,339 $219,000
Q4 2023 Feb 14, 2024	BUY	$1.28 - $2.85 $186,679 - $415,652	145,843 Added 349.85%	187,530 $382,000
Q2 2023 Aug 14, 2023	SELL	$1.66 - $3.03 $1.69 Million - $3.09 Million	-1,018,551 Reduced 96.07%	41,687 $81,000
Q1 2023 May 12, 2023	BUY	$2.13 - $3.74 $1.99 Million - $3.49 Million	934,149 Added 740.86%	1,060,238 $2.95 Million
Q4 2022 Feb 10, 2023	BUY	$2.17 - $3.92 $153,748 - $277,739	70,852 Added 128.27%	126,089 $435,000
Q3 2022 Nov 14, 2022	BUY	$2.46 - $4.75 $70,110 - $135,375	28,500 Added 106.59%	55,237 $142,000
Q2 2022 Aug 12, 2022	SELL	$1.77 - $4.34 $85,745 - $210,246	-48,444 Reduced 64.44%	26,737 $64,000
Q1 2022 May 16, 2022	SELL	$4.03 - $12.19 $633,640 - $1.92 Million	-157,231 Reduced 67.65%	75,181 $310,000
Q4 2021 Feb 08, 2022	BUY	$8.76 - $13.71 $1.85 Million - $2.9 Million	211,548 Added 1013.94%	232,412 $2.99 Million
Q3 2021 Nov 15, 2021	BUY	$6.41 - $13.54 $45,434 - $95,971	7,088 Added 51.45%	20,864 $225,000
Q2 2021 Sep 13, 2021	BUY	$8.13 - $10.2 $111,998 - $140,515	13,776 New	13,776 $125,000

Others Institutions Holding GRTS

# of Institutions

Shares Held

37.5M

Call Options Held

1.46M

Put Options Held

168K

View Full List

About Gritstone bio, Inc.

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $1.46M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

More about GRTS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Gritstone Bio, Inc. Transaction History